A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
about
HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cellsSRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatmentNew cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancerMcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells.AURKA induces EMT by regulating histone modification through Wnt/β-catenin and PI3K/Akt signaling pathway in gastric cancer.Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation.Multi-kinase inhibitors, AURKs and cancer.Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.Protein Kinase Targets in Breast Cancer.MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells.Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer.Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers.A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells
P2860
Q54904340-77D4F52C-0F9F-4F74-B007-FCBAA0B1B77BQ54904341-41AB120E-10EC-429D-8D81-D3862682F4D1Q54904342-27A311C4-9719-421F-836D-E31223C9B593Q54904343-CABE56E3-CEBD-4640-90F3-2662B5B3B7ECQ54904381-E5BC3B98-6F48-452E-A6F1-F82F001B0B65Q54904382-13F0ACDB-BF0A-42D5-8DEB-37C01CE44EA2Q54904383-146371BD-778B-41AC-AD8D-D5C900AA7A42Q54904384-0A33B4B3-7E92-4B76-9DBA-832799113749Q54971575-7BAC8DFE-01F1-4658-9E05-43B443FB02C2Q54971577-8746B7FC-1B0E-4AE5-BCFD-D210FE2905CBQ54971578-FC2A855D-782C-4B9B-AEA0-4CF607D1FC93
P1343
Q33823200-DFFFAC72-E07A-437D-84C2-B54AC13B442BQ35113027-A91FC21F-EF29-4673-A223-F56506EF07ABQ35168124-345C5CBD-C5D9-4A6D-AACE-06EDF6BB08D3Q35356178-FCF2AC8E-F033-4952-AB81-DB1C474B233EQ35938054-66731A75-8D6A-48C1-8827-268480041BB6Q36998209-C46B078D-E954-44C1-9D5F-B14343710DB9Q37362863-A87F79FB-42C7-4B9C-A1DE-2509E7C46FF0Q37651974-9584C03A-A2CB-49BD-AA54-22BF059DB4EAQ38796360-E9D49DEE-F593-47AD-9FAB-C1B1EA6FDE8CQ42503679-EA68915E-CDA7-447C-A0DB-642F58F1C0F9Q47351355-0ADF7236-CB3A-4FFF-89A7-AF10C220D252Q47410836-21EBCEC2-F6F4-494D-83BD-A64E94334532Q48327802-EC3E30BA-8355-4C5E-B320-F5AC1C722CB0Q48544150-1DC25461-6885-4041-B02B-D43C55694551Q49988930-BC9A089E-51A1-48F5-A5C3-37CA635E9FF4Q58786580-0A643255-C38B-4C00-BFA1-5CACA6720F18
P2860
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
A kinase inhibitor screen iden ...... resistant breast cancer cells.
@en
type
label
A kinase inhibitor screen iden ...... resistant breast cancer cells.
@en
prefLabel
A kinase inhibitor screen iden ...... resistant breast cancer cells.
@en
P2093
P2860
P4510
P356
P1433
P1476
A kinase inhibitor screen iden ...... -resistant breast cancer cells
@en
P2093
A E Lykkesfeldt
A K Duun-Henriksen
A M Pedersen
A V Lænkholm
B B Rasmussen
M B H Thomsen
T Kirkegaard
P2860
P2888
P304
P356
10.1038/ONC.2014.351
P407
P4510
P50
P577
2014-11-03T00:00:00Z
P5875
P6179
1030685832